- Report
- June 2022
- 1500 Pages
Global
From €3748EUR$3,900USD£3,214GBP
- Drug Pipelines
- May 2022
- 400 Pages
Global
From €2883EUR$3,000USD£2,473GBP
- Report
- November 2021
- 222 Pages
Global
From €2883EUR$3,000USD£2,473GBP
- Report
- October 2020
- 285 Pages
Global
From €2307EUR$2,400USD£1,978GBP
- Report
- February 2020
- 600 Pages
Global
From €3845EUR$4,000USD£3,297GBP
- Report
- April 2021
- 180 Pages
Global
From €2883EUR$3,000USD£2,473GBP
- Report
- September 2021
- 258 Pages
Global
From €2643EUR$2,750USD£2,267GBP
€5286EUR$5,500USD£4,533GBP
- Report
- September 2021
- 143 Pages
Global
From €2643EUR$2,750USD£2,267GBP
€5286EUR$5,500USD£4,533GBP
- Report
- December 2021
- 353 Pages
Global
From €2643EUR$2,750USD£2,267GBP
€5286EUR$5,500USD£4,533GBP
- Report
- October 2018
- 141 Pages
Global
From €601EUR$625USD£515GBP
€1201EUR$1,250USD£1,030GBP
- Report
- November 2022
- 251 Pages
Global
From €4767EUR$5,134USD£3,950GBP
- Report
- October 2021
- 210 Pages
Global
From €3604EUR$3,750USD£3,091GBP
- Report
- July 2022
- 165 Pages
Global
From €5719EUR$5,950USD£4,904GBP
- Report
- June 2021
- 100 Pages
Global
From €5719EUR$5,950USD£4,904GBP
- Report
- April 2023
- 200 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- February 2023
- 175 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- April 2020
Global
From €3845EUR$4,000USD£3,297GBP
- Report
- June 2020
- 167 Pages
Global
From €2297EUR$2,390USD£1,970GBP
- Report
- October 2018
- 370 Pages
Global
From €3989EUR$4,150USD£3,421GBP
- Report
- February 2023
- 200 Pages
Global
From €5719EUR$5,950USD£4,904GBP
CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more